* Risky CAR-T treatment associated with four deaths this year * Companies, fresh off CAR-T cancer success, pour money into autoimmune disease trials * About 150 lupus-focused CAR-T trials are underway
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Stellar H1 FY27 performance; Acquires 76% stake in SageRoute Logistics, a proposed joint venture entity…
FRANKFURT, Nov 11 (Reuters) - Germany's antitrust authority, the Federal Cartel Office, said on Wednesday…
By Maria Rugamer and Sabine Siebold BERLIN, Nov 11 (Reuters) - German defence technology company…
(Adds comments from MMG, detail in paragraph 2-5) By Melanie Burton MELBOURNE, Nov 11 (Reuters)…
Nov 11 (Reuters) - MANNAI CORPORATION: * MANNAI AWARDED MAJOR MEP AND TECHNOLOGY CONTRACT FOR…
Nov 11 (Reuters) - Futures tracking the S&P 500 and the Nasdaq 100 indexes bounced…